Issued on behalf of VentriPoint Diagnostics Ltd.
VANCOUVER – Baystreet.ca News Commentary – Healthcare providers shortened buying cycles from eight months to under seven as financial pressures force CFOs to demand proven returns over experimental pilots[1]. Half of all practices now deploy AI tools that deliver measurable workflow improvements, shifting industry focus from point solutions to scalable platforms that can generate recurring revenue across multiple use cases[2]. This commercialization wave favors companies building infrastructure moats rather than single-purpose applications, with platform economics emerging as the key differentiator between winners and also-rans. VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), Absci Corporation (NASDAQ: ABSI), Caris Life Sciences (NASDAQ: CAI), Lunai Bioworks (NASDAQ: LNAI), and CareCloud, Inc. (NASDAQ: CCLD, CCLDO) represent this strategic pivot toward platform architectures that address multiple revenue streams within their respective domains.
Hospital systems report average returns of $3.20 for every dollar invested in AI, with typical payback periods reaching just 14 months[3]. Organizations demonstrating clear ROI and seamless integration capture disproportionate market share as buyers prioritize vendors who can prove economic value over those promising future breakthroughs, creating a winner-take-most dynamic that rewards platform players with expanding use cases and sticky customer relationships[4].
Ventripoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF) just announced a partnership with Nisg_a'a Valley Health Authority that establishes a global model for delivering advanced cardiac imaging to remote and Indigenous communities. The collaboration centers on Ventripoint's VMS+ system, which transforms standard 2D ultrasound images into 3D volumetric models with MRI-level accuracy. This technology enables precise cardiac assessments at the point of care, reducing costs and eliminating the need for time-consuming MRI scans.
The model follows a hub-and-spoke design where a central hub with advanced cardiac capabilities supports connected sites in smaller, remote, and Indigenous communities. Local healthcare providers can acquire ultrasound scans and transmit them digitally to specialists at the hub for rapid interpretation. The Nisg_a'a Valley Health Authority will serve as the first remote site in this network, linked to a regional center with tertiary and quaternary care capabilities.
"Through our collaboration with the Nisg_a'a Nation, we are creating a scalable model of heart care that can extend from the Arctic to the Amazon, ensuring that everyone, regardless of geography, has access to advanced diagnostics," said Hugh MacNaught, CEO of Ventripoint.
Future phases are intended to include additional First Nations communities across Canada, Arctic regions, and rural communities worldwide, including areas in the Amazon, Africa, and India where MRI access is limited. The model delivers advanced cardiac imaging directly to patients without the need for long-distance travel, high costs, or extended wait times.
"Partnering with Ventripoint allows us to explore innovative tools that support more accurate diagnoses, faster treatment decisions, and truly patient-centred care right here at home," said Corinne McKay, CEO of Nisga'a Valley Health Authority. "For NVHA, this collaboration is about more than technology. It is about advancing health sovereignty for the Nisg_a'a Nation and strengthening our ability to serve our people with excellence, compassion, and cultural integrity."
The company also recently appointed David Swetlow as Chief Financial Officer in October. Swetlow brings over 15 years of senior management experience from high-growth medical technology companies, including Sernova, Ondine, Protox, HealthPricer, and QLT. Management views the appointment as a key step in executing a refreshed commercial strategy designed to drive market adoption and revenue growth across international markets.
In late October, Ventripoint announced a collaboration with Providence Health Care Ventures to validate VMS+ at St. Paul's Hospital in Vancouver. The study will evaluate whether AI-enhanced echocardiography can reduce demand for cardiac MRI scans at one of Western Canada's leading cardiac programs. Implementation is expected to begin in early 2026.
The company also issued a corporate update detailing its shift toward a Device-as-a-Service subscription model. Management believes this approach will shorten sales cycles and build recurring revenue. The update noted that qualified leads from Europe and North America are increasing, and that Ventripoint's European distributor AngioPro has recommitted to the company and invested additional capital.
CONTINUED… Read this and more news for VentriPoint Diagnostics at: https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripoint
In other industry developments and happenings in the market include:
Absci Corporation (NASDAQ: ABSI) reported third quarter 2025 results while advancing ABS-201 across two high-value indications, with Phase 1/2a trials for androgenetic alopecia starting December 2025 and Phase 2 endometriosis trials planned for fourth quarter 2026. The company's generative AI protein design platform delivered interim Phase 1 data for ABS-101 demonstrating extended half-life compared to first-generation anti-TL1A programs, with Absci now exploring partnership opportunities for this asset.
"This quarter marks a pivotal inflection point for Absci as we sharpen our focus on ABS-201, advancing this program in two high-value indications with strong biological rationale and significant unmet need," said Sean McClain, Founder and CEO of Absci. "Our strategy reflects disciplined execution and confidence in the power of generative AI protein design to deliver breakthrough therapeutics."
Absci is targeting approximately 80 million individuals in the U.S. with androgenetic alopecia and an estimated 9 million women affected by endometriosis, conditions with significant unmet medical needs. The company reported cash, cash equivalents, and marketable securities of $152.5 million as of September 30, 2025, sufficient to fund operations into the first half of 2028.
Caris Life Sciences (NASDAQ: CAI) expanded its Precision Oncology Alliance to 98 cancer centers globally with the addition of UAMS Winthrop P. Rockefeller Cancer Institute, bringing the network's NCI-designated centers to 45 institutions collaborating on AI-driven biomarker research. The alliance leverages comprehensive genomic, transcriptomic, and proteomic data through advanced machine learning platforms to accelerate precision medicine discoveries.
"It is great to welcome UAMS to the Caris POA," said James Hamrick, Chairman of the Caris POA. "Together, we will leverage shared data and cutting-edge AI to accelerate research and translate it into personalized care for patients in Arkansas and around the world."
The platform provides member institutions access to one of the industry's largest multi-modal databases containing matched molecular and clinical outcomes data from hundreds of thousands of cancer patients. Caris aims to establish molecular testing standards through collaborative research designed to improve clinical outcomes while identifying beneficial trial opportunities across its global network.
Lunai Bioworks (NASDAQ: LNAI) secured its first licensing Letter of Intent following breakthrough results showing complete regression of primary and metastatic pancreatic tumors with no recurrence in humanized preclinical models. The company's Dendritic Cell Combination Therapy achieved 80 to 90 percent reduction in tumor size across two independent studies targeting pancreatic cancer, which has a five-year survival rate of just 13 percent.
"We are seeing accelerating validation from both researchers and industry partners," said David Weinstein, CEO of Lunai Bioworks. "Independent expert analysis confirms the strength of our data, while early licensing activity reflects growing confidence in this platform's potential to unlock scalable, off-the-shelf treatments capable of reaching the patients who need them most."
The allogeneic immunotherapy is manufactured from healthy donor cells and stored ready-to-use, reducing manufacturing timelines from weeks to days while lowering overall treatment costs. Lunai is preparing for formal licensing negotiations and pre-IND activities in early 2026, with collaborations expanding to non-small cell lung cancer with UCLA and prostate cancer studies with UC Irvine.
CareCloud, Inc. (NASDAQ: CCLD, CCLDO) delivered third quarter 2025 revenue of $31.1 million, up 9% year-over-year, marking its sixth consecutive quarter of positive GAAP net income as the company's AI Center of Excellence scales across its healthcare technology platform. The company raised its full-year 2025 revenue guidance to $117-119 million from an initial range of $111-114 million, reflecting successful integration of the Medsphere and Map App acquisitions that expanded its reach across hospital ambulatory and inpatient care settings.
"Our recent acquisitions and AI initiatives are working hand in hand to create meaningful value for our clients and shareholders," said A. Hadi Chaudhry, Co-CEO of CareCloud. "By infusing AI into acquired platforms, we're enhancing performance, driving efficiency, and opening new cross-sell and up-sell opportunities that strengthen CareCloud's long-term growth trajectory."
The company's suite of generative AI solutions serves more than 45,000 providers, with technology-enabled offerings spanning revenue cycle management, practice management, electronic health records, and patient experience management. CareCloud reported adjusted EBITDA of $7.7 million, up 13% year-over-year, while maintaining positive cash flow generation that funded the remaining balance of the Medsphere acquisition and continued monthly preferred stock dividends.
Article Source: https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripoint
CONTACT:
Baystreet.ca
[email protected]
(805) 649-0042
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. This article is being distributed for Baystreet.ca media Corp, who has been paid a fee for an advertising campaign. There may also be 3rd parties who may have shares of Ventripoint Diagnostics Ltd. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of BAY own shares of Ventripoint Diagnostics Ltd and reserve the right to buy and sell, and will buy and sell shares of Ventripoint Diagnostics Ltd. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by BAY has been approved by Ventripoint Diagnostics Ltd.; this is a paid advertisement, we currently own shares of Ventripoint Diagnostics Ltd. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
--
SOURCES CITED:
1. https://menlovc.com/perspective/2025-the-state-of-ai-in-healthcare/
2. https://www.medicaleconomics.com/view/ai-adoption-accelerates-across-medical-practices-survey-shows
3. https://www.demandsage.com/ai-in-healthcare-stats/
4. https://www.medicaleconomics.com/view/ai-adoption-accelerates-across-medical-practices-survey-shows